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Non-vitamin K oral anticoagulants (NOACs) are currently recommended for patients with 
non-valvular atrial fibrillation (NVAF) since the publication of the four major pivotal trials 
evaluating the efficacy and safety of factor IIa and factor Xa inhibitors. The definition of 
NVAF is unclear, varying from one trial to another, and even between North-American and 
European guidelines, which is a source of uncertainties in clinical practice. However, many 
patients with atrial fibrillation (AF) present signs of valvular involvement, and clarification of 
this term is needed in order to not deny NOACs to patients based on the wrong perception that 
they may have valvular AF.  
The currently unique contraindications to NOACs are patients with mechanical heart valves 
and those with moderate-to-severe mitral stenosis, as stated by the recent 2015 position paper 
of the European Heart Rhythm Association. Patients with native heart valve involvement, 
regardless of their severity are suitable for NOAC therapy. Patients with bioprosthetic heart 
valves and mitral valve repair may be suitable for NOACs except for the first 3 and the first 3-
6 months post-operatively, respectively. Patients with transaortic valve implantation (TAVI)
or percutaneous transluminal aortic valvuloplasty are also considered as being eligible for 
NOACs, although the bleeding risk has to be carefully considered in this population often 
requiring a combination with antiplatelet therapy. 
Future studies are warranted to increase the level of evidence of use of NOACs, particularly 
in patients with TAVI and valvular surgery, and to determine whether they could be used in 














Atrial fibrillation (AF) is the most common arrhythmia in clinical practice, with currently in 
Europe approximately 10 million patients with AF and 100,000–200,000 with new-onset AF.1
This arrhythmia has a high morbidity and mortality risk, mainly due to the elevated risk of 
ischemic stroke. The CHA2DS2VASc score is a validate tool to estimate the annual risk of 
stroke or systemic embolism, ranging from less than 1% to approximately 20% in the absence 
of oral anticoagulants.2
Historically, vitamin-K antagonists (VKA) were the gold-standard treatment for the 
prevention of systemic embolism. However, this therapy has many downsides, like the 
interactions with food and other drugs, a narrow therapeutic window, the need for frequent 
coagulation monitoring and dosage adjustment, or its’ particular pharmacokinetics (delayed 
onset and offset of anticoagulant effect) somehow complicating the management of patients. 
Recently, non-VKA Oral Anticoagulants (NOAC) have been introduced. This therapeutic 
class facilitates the management of oral anticoagulation since the four currently available 
molecules do not have most of the downsides described above. Though, its use is 
contraindicated in patients with severe renal impairment and with so-called “valvular AF”. 
The definition of valvular and non-valvular AF (NVAF) are unclear, varying from one to the 
other NOAC study, 3-6 and even between North-American and European guidelines,7, 8 which 
is a source of ambiguity in clinicians’ minds. A clarification of the term NVAF is needed in 
order to not deny NOACs to patients based on the wrong perception that they may have 
NVAF. 
In the present comprehensive review, we aimed at clarifying this point, by analyzing results of 
the main randomized trials in the area and recommendations in current guidelines and by 
describing the safety and efficacy of NOACs in patients with valvular abnormalities, based on 
the results of published studies. 
The magnitude of the problem 
A large proportion of the patients with AF have signs of valvular involvement. Among those 
included in the EURObservational Research Programme Atrial Fibrillation, a prospective 
survey in european countries, 63.5% had a valvular disease.9 The presence of such anomalies 
increase the risk of AF by 1.8 and 3.4 in men and women, respectively.10 On the other hand,
animal studies have shown that AF, through atrial dilatation, results in a progressive mitral 
regurgitation, already present at the transition stage between paroxysmal and persistent AF, 













relationship between both anomalies is frequent and often unclear, particularly in the presence 
of atrial dilatation.  
From NOAC trials to current guidelines 
Factor IIa (dabigatran) and factor Xa (rivaroxaban, apixaban, and edoxaban) inhibitors have 
demonstrated their non-inferiority or superiority compared to VKA to reduce the risk of 
stroke and systemic thrombo-embolism.3-6 In the meta-analysis published in 2014 by Ruff et 
al12 compelling the 4 major trials on stroke prevention for AF published so far, a significant 
reduction of 19% of this endpoint was observed. Importantly, major bleedings were 
significantly reduced by 14%. In these seminal trials, patients with contra-indications to 
NOACs were excluded, including those with chronic kidney disease or in case of treatment 
interactions. One of the major exclusion criteria was the presence of a “valvular” AF, but the 
definition varied widely between the pivotal trials. As shown in Table 1, the inclusion criteria 
of the RE-LY,4 the ROCKET-AF,6 the ARISTOTLE,3 and the ENGAGE-AF TIMI 485 trials 
were substantially dissimilar. The most restrictive study was the RE-LY trial,4 since a “history 
of heart valve disorder (i.e., prosthetic heart valve or hemodynamically relevant valve 
disease)” was an exclusion criterion. The definition of the “hemodynamically” relevance of a 
valvular involvement is unclear, since it may suggest the presence of clinical and/or 
echocardiographic parameters of intolerance. Conversely, the ARISTOTLE3 and the 
ENGAGE-AF TMI 485 trials had more lenient inclusion criteria, allowing the inclusion of 
patients with bioprosthesis or mitral valve repair. To note, the term NVAF only appears in the 
ROCKET-AF trial,6 the other trials having avoided to overuse it. 
The current ESC guidelines for the management of AF published in 2012 rightly state that 
there is “no satisfactory or uniform definition” of NVAF, and authors defined NVAF as AF 
related to “rheumatic valvular disease (predominantly mitral stenosis) or prosthetic heart 
valves”.7 These two conditions are the only one contraindicating the use of NOACs in patients 
with AF in European guidelines. In the more recent 2014 AHA/ACC/HRS guidelines for the 
management of AF, AF is defined as “valvular” when associated with “rheumatic mitral 
stenosis, a mechanical or bioprosthetic heart valve, or a mitral valve repair”.8 Thus, one can 
appreciate the discrepancy between European and North-American guidelines, since patients 
with mitral valve repair are eligible for NOACs in one side of the Atlantic but not in the other. 
Such divergences, in conjunction with physicians’ fear about ischemic embolism and its 
potential forensic consequences, complicate the therapeutic decision of prescribing or not 













physicians’ minds the absence of any given valvular involvement to allow the prescription of 
NOACs. A recent study assessed the different aspects of the definition of NVAF by 
conducting a web-based survey filled by a total of 513 Italian cardiologists and internists.13 To 
the question “Do you think that the existing definitions of NVAF are sufficiently clear?”, 57.1 
and 67.9% of them answered “yes”, respectively. Surprisingly, the answers of the following 
questions were not in accordance with this initial result. Indeed, for 28.2% of the 
cardiologists, the presence of a mitral regurgitation alone was sufficient to define AF as 
valvular AF, and 26.7% defined patients with biological aortic valve prosthesis as having 
NVAF. A clarification of the term NVAF is then urgently needed in order to homogenize 
current clinical practice and remove uncertainties regarding this common issue. 
Valvular heart diseases, AF and thrombo-embolic risk 
Mitral stenosis 
Mitral stenosis has historically been considered a distinct disease in the area of AF. Indeed, it 
results in a low atrial flow, significantly increasing the risk of atrial thrombi, which, besides, 
are often located in various regions of the atria but the left atrial appendage (91% in NVAF 
and 57% in AF associated with mitral stenosis).14 Since the thrombo-embolic risk is 
increased, and the efficacy of new anticoagulants uncertain, such patients were excluded from 
randomized controlled trials about NOACs, and to date, there are no data regarding the 
efficacy and safety of these molecules in patients with mitral stenosis. Whether 
pathophysiology of thrombi genesis in these patients is substantially different to 
contraindicate NOAC prescription is unknown and would probably require further studies. 
Other valvular diseases 
The other valvular diseases (mitral or tricuspid regurgitations, aortic stenosis) were not 
considered to increase per-se the risk of thrombo-embolic event. However, Philippart et al 
recently demonstrated that patients with left-sided valvular disease had a 1.39-fold increase 
risk of stroke/thrombo-embolic events, probably explained by a higher CHA2DS2-VASc score 
and significantly more comorbidities in these patients, compared to those with no valvular 
diseases.15 Indeed, older age and higher CHA2DS2-VASc scores were the only independent 
predictors of ischemic events, but not the presence of a valvular disease. 
Many studies have shown that mitral regurgitation might reduce the risk of stroke since atrial 













This phenomenon has been described especially in case of severe regurgitation, and not 
demonstrated for mild or moderate regurgitations.16, 17 Regarding aortic stenosis, one have to 
keep in mind that calcic microemboli may occur, and that stroke in the presence of AF may 
have a different pathophysiologic origin. 
Data regarding the use of rivaroxaban and apixaban in patients with valvular involvement 
have recently been published. Among the 14 171 patients included in the ROCKET-AF trial, 
2003 (14.1%) had a valvular disease, mainly mitral or aortic regurgitations (respectively 
89.6% and 24.8% of the patients) or aortic stenosis (11.0%), half of them from degenerative 
origin. The severity of those valvular diseases was not reported.18 To note, 5.3% had prior 
cardiac valvular surgeries. Baseline characteristics of patients with or without valvular 
involvement significantly differed, since the former were older and had more comorbidities 
like congestive heart failure, prior myocardial infarction, chronic obstructive pulmonary 
disease or smoking. Although rivaroxaban had a similar efficacy in patients with or without 
valvular disease, a significant lower bleeding rate was observed in the latter group, probably 
explained by the differences in terms of baseline characteristics. The interaction of valvular 
disease in patients randomized to rivaroxaban and warfarin was not significant in intention-to-
treat in terms of efficacy outcomes. However, a significant higher bleeding rate was observed 
in patients with valvular involvement randomized to rivaroxaban compared to warfarin. 
A similar analysis was performed among patients included in the ARISTOTLE trial 
comparing efficacy and safety outcomes in patients randomized to apixaban or warfarin.19
Among the 18 201 patients included, 4808 had valvular heart diseases (26.4%), including 
mitral, tricuspid and aortic regurgitations, or aortic stenosis, with various grades of severity 
(from mild to severe). To note, a total of 465 patients with mild mitral stenosis were included, 
as were 251 patients with prior valve surgeries (see below for details). As previously 
described in the subanalysis of the ROCKET-AF trial, patients with valvular heart diseases 
were older and had more comorbidities; CHADS2 score was also significantly higher in this 
group. Patients with valvular heart disease had higher rates of stroke or systemic embolism 
(3.2% versus 2.4%; HR, 1.34; 95% CI, 1.10–1.62; p=0.003) and bleeding (4.6% versus 4.3%;
HR, 1.11; 95% CI, 0.95–1.29; p=0.21) compared to patients without valvular heart diseases. 
However, no differential effect of apixaban over warfarin in patients with and without 
valvular diseases in reducing stroke and systemic embolism was observed. Similarly, bleeding 
and mortality were similar among patients randomized to apixaban or warfarin, whether 













As previously stated, the NOAC trial with the most restrictive inclusion criteria was the RE-
LY trial. Results about the outcomes of patients with valvular heart diseases included in this 
trial (21.0% of the population) have not been published yet but presented as preliminary 
form.20 Similarly to the results of the subanalysis of the ROCKET-AF and the ARISTOTLE 
trials, the benefit of dabigatran in reducing stroke and systemic embolism, major bleeding and 
life-threatening or intracranial bleeds, were similar in patients with valvular diseases 
compared to those without. Similar data for patients included in the ENGAGE-AF TIMI 48 
trial and receiving edoxaban have not been published or presented so far. In summary, 
patients with valvular diseases are not at higher risk of stroke per-se, but are often older, with 
several comorbidities, and consequently have a higher thrombo-embolic (CHA2DS2-VASc) 
score, putting them at risk for stroke and embolic complications of AF independently of the 
type of anticoagulant. NOACs appear to have similar efficacy and safety profiles irrespective 
to the presence of a valvular disease. In parallel to the CHA2DS2-VASc score, hemorrhagic 
scores (HAS-BLED or HEMORRAGE scores) are also often increased, and one have to keep 
in mind that a careful attention is required when NOACs are prescribed in such patients. 
Mechanical valves 
Patients with mechanical valves are at a high risk of thrombo-embolic complications and 
require permanent anticoagulation after valve implantation. Warfarin has been shown to 
decrease this risk to an annual rate of 0.7-1%.21, 22 Thrombi may form directly in the surface 
of the valve or in the left atrial appendage as a consequence of the low-flow induced by the 
presence of the valve. During the post-operative time or later during follow-up, AF may 
appear, further increasing thrombo-embolic risk. The phase-2 RE-ALIGN study was designed 
to test the safety and efficacy profile of dabigatran in patients with aortic and/or mitral 
mechanical prosthesis.23 Drug doses varied from 150 mg x 2 to 300 mg x 2 depending on 
kidney function and blood concentrations of the molecule. Two populations of patients were 
studied, i.e. those with early (< 7 days) or late (> 3 months) initiation of dabigatran after the 
surgery. The trial was terminated prematurely since the use of dabigatran in patients with 
mechanical prosthesis was associated with an increased risk of thromboembolic and major 
bleeding complications (5% vs. 0%, and 4% vs 2%, respectively) compared to warfarin. Most 
thrombo-embolic events occurred in patients from the early-initiation group, while bleeding 
events occurred similarly in both groups. However, major bleeding occurred only in patients 
for whom dabigatran was initiated early after the valve implantation, all being pericardial 













anticoagulation after the implantation of a mechanical heart valve, and VKAs remain the 
gold-standard treatment in such patients. 
Bioprosthesis 
The antithrombic strategy after bioprosthesis valve implantation is currently controversial, but 
most of the times, aspirin may be a safe option in such patients in sinus rhythm.24-27 Whenever 
AF occurs, an oral anticoagulation has to be prescribed.26 As recently demonstrated, the 
presence of a bioprosthesis is associated with a non-significant increase in 
stroke/thromboembolic events but is not independently associated with their occurrence.28
Whether pathophysiology of thrombi formation is sufficiently different in these patients to 
contraindicate NOAC prescription is unknown. 
The only dedicated trial was the DAWA study (Dabigatran versus warfarin after mitral and/or 
aortic bioprosthesis replacement and atrial fibrillation postoperatively) was designed to 
compare dabigatran (at a dose of 110 mg x 2) with warfarin in patients with bioprostheses,29
but results cannot be interpreted due to the very limited number of patients enrolled.30
To date, the only data available on the efficacy and safety profiles of NOACs in patients with 
bioprosthesis come from subgroup analyses. The ARISTOTLE trial brings us some insights 
about this specific group of patients, with data recently presented at the 2015 AHA meeting.31
As stated above, 251 patients (1.7%) included in the ARISTOTLE trial had a history of valve 
surgery. Details on the valve surgery were not collected at the time of the trial but gathered 
retrospectively after the completion of the study, and were completely available for 165 
patients. Baseline clinical characteristics of patients with bioprothetic aortic and/or mitral 
valves receiving apixaban (N=56) or warfarin (N=52) were similar. Efficacy (stroke and 
systemic embolism) and safety outcomes (major bleeding, intracranial hemorrhage, 
cardiovascular and all-cause death) were similar among both groups. Data about patients with 
bioprosthetic heart valves included in the ENGAGE-AF TIMI 48 trial (the only trial having 
clearly stated this inclusion criterion) have not been presented so far. 
Trans-aortic valve implantation 
Trans-aortic valve implantation (TAVI) has emerged as an alternative to surgical aortic valve 
replacement for patients with aortic stenosis. Antithrombic management after implantation 
remains empiric, often based on a dual antiplatelet therapy, associating aspirin and 
clopidogrel for 3 to 6 months, followed by long-term aspirin or a thienopyridine alone.25-27













ESC and the European Association for CardioThoracic Surgery recommend a combination of 
VKA and aspirin or thienopyridine, weighed against increased risk of bleeding.26  Similarly to 
what was stated for bioprosthetic valves, whether pathophysiology of thrombi formation is 
sufficiently different in TAVI patients to contraindicate them to NOACs would require further 
studies, and to the best of our knowledge, there are no data published so far in the literature in 
this topic.
Moving towards new recommendations? 
In 2015, the European Heart Rhythm Association (EHRA) published a practical guide on the 
use of NOACs in patients with AF.32 In this position paper, authors state that NVAF refers to 
“AF that occurs in the absence of mechanical prosthetic heart valves and in the absence of 
moderate-to-severe mitral stenosis”, and add that patients with biological valves or valve 
repair are in a “grey area” and may be suitable for NOAC prescription. Indeed, it is stated that 
patients with bioprosthetic heart valves and mitral valve repair are suitable for NOAC therapy 
except for the first 3 and the first 3-6 months post-operatively, respectively. Patients with 
TAVI or percutaneous transluminal aortic valvuloplasty are also considered as being eligible 
for NOACs, although the bleeding risk has to be carefully considered in this population often 
requiring a combination with antiplatelet therapy. The only remaining contraindications of 
NOAC remain mechanical prosthetic valves and moderate-to-severe mitral stenosis, while 
patients with other native valvular diseases are not considered as having valvular AF, 
regardless of severity. A flow chart to guide decision making is depicted in the Figure. 
Future perspectives 
Elderly patients are at risk of AF and may at some point present with a degenerative calcific 
aortic stenosis, requiring surgery or percutaneous therapy. To date and as stated above, there 
is a clear lack of evidence of NOAC suitability in such patients. Thus, studies analyzing the 
safety and efficacy profile of NOACs in patients with bioprosthetic heart valves and TAVI are 
urgently warranted. 
Lifelong oral anticoagulation with VKAs is mandatory for patients with mechanical heart 
valves to prevent thromboembolic complications although lability of INRs is a major 
drawback in this situation, requiring strict coagulation monitoring and drug-adjustments. 
Initial promising results of in-vitro and animal studies showing the efficacy of dabigatran in 
preventing valve thrombosis raised hope about use of NOACs in patients with mechanical 













vitro coagulation studies later demonstrated that mechanical heart valves induce a local 
generation of thrombin via the intrinsic pathway in concentrations that overwhelm the 
inhibitory effect of dabigatran at clinical doses,35 probably explaining the negative results of 
the trial. Whether a similar effect occurs with factor Xa inhibitors would require further 
studies. Preliminary in-vitro36 and animal37 studies demonstrated that high-dosed rivaroxaban 
might be effective in preventing thromboembolic events after mechanical heart valve 
replacement. However, in the light of the results of the RE-ALIGN trial,23 further studies 
would be needed to provide additional data to support clinical trials evaluating factor Xa 
inhibitors as an alternative to warfarin in patients with prosthetic heart valves. 
Patients with moderate-to-severe mitral stenosis (usually of rheumatic origin) have not been 
included in NOAC trials on the basis of a potential higher risk and different pathophysiologic 
mechanism of thrombi formation. The prevalence of rheumatic heart disease, the most
common cause of mitral stenosis, is widely variable, remaining a major problem in 
developing areas of the world. Irrespective to atrial rhythm, thrombo-embolic strokes are 
frequent, estimated to reach around 4 million events per year. Oral anticoagulation using 
VKAs is recommended in patients with mitral stenosis and AF, and may be proposed to 
patients with mitral stenosis in the absence of AF.24-27 However, times in therapeutic range, 
already suboptimal in developed countries, are even worst in developing parts of the world 
with high incidence of rheumatic fever.38 Alternative therapeutic strategies, such as aspirin, 
are sometimes offered to such patients, despite the well-known inferiority to VKAs.2 Based 
on these assumptions, De Caterina and Camm recently wrote “the concept for a trial” 
comparing NOACs to the standards of care for thromboembolic prophylaxis (antiplatelet 
agents or VKA) in patients with mitral stenosis.39 They claim that a randomized, open-label, 
superiority trial should be conducted in specific countries with a high prevalence of mitral 
stenosis using a NOAC available for once daily use (rivaroxaban or edoxaban) to facilitate 
patients’ compliance, at the same dosage used in pivotal trials in AF. The overall sample size 
would vary depending on the expected stroke rate, the study duration and the expected hazard 
ratio of stroke reduction, from around 600 to 7000. Such study appears to be feasible, at least 
by academic centers, if not by pharmaceutical companies, and is warranted to improve the 
suboptimal current standard antithrombotic treatment of patients with mitral stenosis. 
Lastly, it may be now time to stop using the confusing term “non-valvular” to define a type of 
AF. As stated by De Caterina and Camm, a novel terminology should be used in order to 
clarify this confusion situation.40 Authors proposed the term “MARM-AF”, acronym standing 













contraindications to NOACs. The future will tell us whether this term will be life-standing and 
used by futures researchers. 
Conclusion 
The term “NVAF” and the inclusion and exclusion criteria in NOACs pivotal trials have 
created some confusion in physicians’ minds about patients who are eligible or not to this 
therapy. Evidences are progressively coming and showing that NOACs can be safely used in 
patients with native valvular diseases, regardless of their severity, and probably in 
bioprosthetic heart valve recipients. The only contraindications remain the presence of a 
mechanical heart valve and moderate-to-severe mitral stenosis. Future studies are warranted 
to increase the level of evidence of the safety and efficacy of NOACs in specific populations,
particularly in patients with TAVI and bioprosthetic valve, and to determine whether they 
could be used in the future in the two remaining contraindications. 
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Trial Molecule Exclusion criteria
RE-LY Dabigatran
History of heart valve disorder (i.e., prosthetic valve or 
hemodynamically relevant valve disease)
ROCKET-AF Rivaroxaban
Hemodynamically significant mitral valve stenosis, prosthetic 
heart valves (annuloplasty with or without prosthetic ring, 
commisurotomy and/or valvuloplasty are permitted)
ARISTOTLE Apixaban
Conditions other than AF that require anticoagulation (i.e. 
prosthetic heart valves)
ENGAGE AF Edoxaban
Moderate-to-severe mitral stenosis, other indication for 
anticoagulation (subjects with bioprosthetic heart valves and/or 
valve repair could be included)
Table 1.Inclusion criteria in NOACs pivotal trials. 


























ESC 2012 X X X X √ √
HRS/ACC/AHA 2014 X X X X X √
EHRA 2015 X X
√
Except for the 















Table 2. Guidelines about NOACs use in patients with valvular diseases. 
X = Contraindicated; √ = Eligible; ACC = American College of Cardiology; AHA = 
American Heart Association; EHRA = European Heart Rhythm Association; ESC = European 
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